

Supplementary Material

Activated carbon coupled with advanced biological wastewater treatment: a review of the enhancement in micropollutant removal

Marina Gutiérrez¹, Vittoria Grillini¹, Dragana Mutavdžić Pavlović², Paola Verlicchi^{1*}

1. Department of Engineering, University of Ferrara, Via Saragat 1, 44122 Ferrara, Italy
marina.gutierrezpulpeiro@unife.it, vittoria.grillini@unife.it, paola.verlicchi@unife.it
2. Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Zagreb, Trg Marka Marulića 19, 10000, Zagreb, Croatia dmutavdz@fkit.hr

* Corresponding Author

Summary

S1. Identification of the studies by PRISMA guidelines

p. 2

List of Tables

Table S1. List of compounds included in the review together with their main chemical and physical properties.

p. 4

Table S2. Main characteristics of the selected studies (Excel file)

Table S3. Compounds for which the removal in MBR is equal or higher than the removal achieved in MBR+PAC

p. 26

Table S4. Compounds for which the removal in MBR is equal or higher than the removal achieved in MBR→GAC

p. 27

List of Figures

Figure S1. Steps of the review according to PRISMA Guidelines

p. 3

Figure S2. Removal efficiencies for the investigated compounds in MBR+PAC with submerged and side stream membrane unit grouped by author

p. 28

Figure S3. Removal efficiencies for the investigated MPs in a GAC column acting as a post treatment (polishing) grouped by the Authors

p. 29

Figure S4. Concentration in the effluent of a PAC/GAC unit acting as a PT (part 1)

p. 30

Figure S5. Concentration in the effluent of a PAC/GAC unit acting as a PT (part 2)

p. 31

Figure S6. Concentration in the effluent of a PAC/GAC unit acting as a PT

p. 32

Figure S7. Removal efficiencies in PAC units acting as a PT for the compounds grouped according to their charge and in descending order according to Log D_{ow}.

p. 33

References

p. 34

S1. Identification of the studies by PRISMA guidelines.

In 2009, international experts established a protocol, known as the PRISMA guidelines, which defines the steps to follow to obtain a systematic review on a specific topic.

Following the guidelines, a research engine (Scopus) was chosen and key terms were identified in order to initially gather a wide collection of peer reviewed papers (records). The combination of terms and Boolean operators: “MBR” OR “membrane bioreactor” OR “membrane reactor” AND “activated carbon” OR “AC” led to a first list containing 379 records. A further 30 records were identified among the references of the collected papers. Out of these 409 records, 252 were rejected in the first screening, resulting in 157 selected records. The first selection was based on the title and the abstract of each record. In particular, eligibility criteria included only peer-reviewed papers written in English and concerning municipal or urban, domestic and hospital wastewater. Records related to drinking water supplies, groundwater injections and industrial processes were excluded as well as records related to reviews (30), book chapters (9) and conference papers (13).

After the first screening, selection criteria were applied to only include membrane bioreactors enhanced/coupled with AC. In this context, configurations including dynamic membranes (5), fluidised bed membrane bioreactors (30), microbial fuel cell bioreactors (6) and a further 47 records related to investigations on specific equipment configurations or conditions which did not fit the scope of the present review were excluded.

As a result of this process, a collection of 64 peer reviewed papers, published between 2009 and 2020, was defined. This included studies presenting and discussing the new trends in the enhancement of the performance of membrane bioreactors in combination with AC, in terms of removal efficiency of macro- (BOD₅, COD, nitrogen compounds, phosphorus compounds) and micro-pollutants, and fouling reduction and control (**Figure S1**). Based on these studies and following the PRISMA guidelines, a qualitative synthesis was carried out. Then a further refinement was carried out, leading to the identification of 26 records on which a quantitative synthesis was carried out referring to removal of MPs in MBR coupled AC (PAC or GAC). The list of 64 papers is reported with the full details at the end of the Supplementary Material, references in bold refer to the 26 records selected for MP removal analysis.

List of papers

(Abegglen et al., 2009)(**Alvarino et al., 2016**)(**Alvarino et al., 2017**)(Asif et al., 2020)(Baresel et al., 2019)(Cho et al., 2011)(Echevarría et al., 2019)(Gao et al., 2016)(Gkotsis et al., 2020)(Grover et al., 2011)(Guo et al., 2008)(Itzel et al., 2018)(Iversen et al., 2009a)(Iversen et al., 2009b)(Johir et al., 2011)(Johir et al., 2013)(Johir et al., 2016)(Jamal Khan et al., 2012)(Kovalova et al., 2013)(Langenhoff et al., 2013)(Lee et al., 2009)(Lee et al., 2010)(Lee et al., 2016)(Lei et al., 2019)(Li et al., 2011)(Lin et al., 2011)(Lipp et al., 2012)(Löwenberg et al., 2014)(Ma et al., 2014b)(Ma et al., 2014a)(Margot et al., 2013)(Mohamadi et al., 2019)(Navaratna et al., 2016)(Ng et al., 2013)(**Nguyen et al., 2012**)(**Nguyen et al., 2013a**)(**Nguyen et al., 2013b**)(**Nguyen et al., 2014**)(Nielsen et al., 2013)(Pan et al., 2016)(Paredes et al., 2018)(Paulus et al., 2019)(Plakas et al., 2016)(Remy et al., 2010)(Remy et al., 2012)(Sbardella et al., 2018)(Serrano et al., 2011)(Torretta et al., 2013)(Wang et al., 2016)(Wei et al., 2016)(Wong et al., 2016)(Woo et al., 2016)(Woo et al., 2020)(Xiao et al., 2017)(Yang et al., 2010)(Yang et al., 2012)(Yang et al., 2019)(Yu et al., 2014)(Zhang and Zhao, 2014)(Zhang et al., 2017)(Zhang et al., 2019b)(Zhang et al., 2019a)(Ziemba et al., 2020)(Zouboulis et al., 2017)

















Figure S1. Steps of the review according to PRISMA Guidelines.

Table S1. List of compounds included in the review together with their main chemical and physical properties








Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	Log K_{ow}	Strongest acidic pK _a	Strongest basic pK _a	Log D_{ow} (pH=6)	Log D_{ow} (pH=8)	Charge (pH=7)	A,N,Z,C*
Analgesics/Anti-inflammatories	4-Acetamidoantipyrine	245.28		C13H15N3O2	0.15	12.52	--	0.15	0.15	0	N
Analgesics/Anti-inflammatories	4-Aminoantipyrine	203.25		C11H13N3O	0.33	--	0.07	0.33	0.33	0	N
Analgesics/Anti-inflammatories	4-Formylaminoantipyrine	231.26		C12H13N3O2	0.11	12.66	--	0.11	0.11	0	N
Analgesics/Anti-inflammatories	4-Methylaminoantipyrine	217.27		C12H15N3O	0.77	--	1.24	0.77	0.77	0	N
Analgesics/Anti-inflammatories	Antipyrine/Phenazone	188.23		C11H12N2O	1.22	--	0.49	1.22	1.22	0	N
Analgesics/Anti-inflammatories	Diclofenac	296.15		C14H11Cl2NO2	4.26	4.00	--	2.26	0.85	-1	A
Analgesics/Anti-inflammatories	Formyl-4-aminoantipyrine	231.26		C12H13N3O2	0.11	12.66	--	0.11	0.11	0	N
Analgesics/Anti-inflammatories	Ibuprofen	206.29		C13H18O2	3.84	4.85	--	2.67	0.85	-0.99	A










Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	Log K_{ow}	Strongest acidic pKa	Strongest basic pKa	Log D_{ow} (pH=6)	Log D_{ow} (pH=8)	Charge (pH=7)	A,N,Z,C*
Analgesics/Anti-inflammatories	Indometacin	357.79		C19H16ClNO4	3.53	3.79	--	1.34	0.08	-1	A
Analgesics/Anti-inflammatories	Ketoprofen	254.29		C16H14O3	3.61	3.88	--	1.51	0.18	-1	A
Analgesics/Anti-inflammatories	Meclofenamic acid	296.15		C14H11Cl2NO2	6.09	3.79	--	3.90	2.64	-1	A
Analgesics/Anti-inflammatories	Mefenamic acid	241.29		C15H15NO2	5.40	3.89	--	3.30	1.97	-1	A
Analgesics/Anti-inflammatories	Morphine	285.34		C17H19NO3	0.90	10.26	9.12	-1.83	-0.03	0.99	C
Analgesics/Anti-inflammatories	N-acetyl-4-aminoantipyrine	245.28		C13H15N3O2	0.15	12.52	--	0.15	0.15	0	N
Analgesics/Anti-inflammatories	Naproxen	230.26		C14H14O3	2.99	4.19	--	1.18	-0.36	-1	A
Analgesics/Anti-inflammatories	Paracetamol/Acetaminophen	151.17		C8H9NO2	0.91	9.46	--	0.91	0.89	0	N









Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	Log K_{ow}	Strongest acidic pKa	Strongest basic pKa	Log D_{ow} (pH=6)	Log D_{ow} (pH=8)	Charge (pH=7)	A,N,Z,C*
Analgesics/Anti-inflammatories	Salicylic acid	138.12		C7H6O3	1.98	2.79	--	-1.06	-1.54	-1	A
Analgesics/Anti-inflammatories	Tramadol	263.38		C16H25NO2	2.45	13.80	9.23	-0.59	1.20	0.99	C
Anaesthetics	Lidocaine	234.34		C14H22N2O	2.84	13.78	7.75	1.09	2.65	0.85	C
Anaesthetics	Thiopental	242.34		C11H18N2O2S	2.78	7.20	--	2.76	1.95	-0.39	N/A
Antibacterials	Amoxicillin	365.40		C16H19N3O5S	-2.31	3.23	7.22	-2.32	-3.04	-0.38	Z
Antibacterials	Ampicillin	349.41		C16H19N3O4S	-2.00	3.24	7.23	-2.02	-2.72	-0.37	Z
Antibacterials	Azithromycin	749.00		C38H72N2O12	2.44	12.43	9.57	-3.64	-0.08	1.99	C
Antibacterials	Cephalexin	347.39		C16H17N3O4S	-2.14	3.26	7.23	-2.16	-2.85	-0.37	Z

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Antibacterials	Ciprofloxacin	331.35		C17H18FN3O3	-0.86	5.56	8.77	-0.96	-0.91	0.05	Z
Antibacterials	Clarithromycin	747.96		C38H69NO13	3.24	12.46	9.00	0.36	2.20	0.99	C
Antibacterials	Clindamycin	424.98		C18H33CIN2O5S	1.04	12.41	7.55	-0.52	0.91	0.78	C
Antibacterials	Doxycycline	444.44		C22H24N2O8	-3.34	3.27	8.33	-3.35	-4.14	-0.34	Z
Antibacterials	Erythromycin	733.94		C37H67NO13	2.60	12.45	9.00	-0.29	1.55	0.99	C
Antibacterials	Flumequine	261.25		C14H12FNO3	2.42	5.81	--	2.01	0.25	-0.94	A
Antibacterials	Lincomycin	406.54		C18H34N2O6S	-0.32	12.37	7.97	-2.28	-0.60	0.9	C
Antibacterials	Metronidazole	171.16		C6H9N3O3	-0.46	15.41	3.03	-0.46	-0.46	0	Z

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Antibacterials	<i>N</i> 4-acetyl sulfamethoxazole	295.31		C12H13N3O4S	0.86	5.88	0.38	0.55	-0.06	-0.93	A
Antibacterials	<i>Norfloxacin</i>	319.34		C16H18FN3O3	-0.97	5.58	8.77	-1.07	-1.01	0.05	Z
Antibacterials	<i>Oflloxacin</i>	361.37		C18H20FN3O4	0.09	5.35	6.72	0.09	-1.02	-0.61	Z
Antibacterials	<i>Oxolinic acid</i>	261.23		C13H11NO5	1.35	5.39	--	0.65	-1.21	-0.98	A
Antibacterials	<i>Oxytetracycline</i>	460.44		C22H24N2O9	-4.54	3.18	8.29	-4.56	-5.46	-0.4	N/A
Antibacterials	<i>Rifaximin</i>	785.89		C43H51N3O11	4.59	6.69	5.88	4.59	3.14	--	--
Antibacterials	<i>Roxithromycin</i>	837.06		C41H76N2O15	3.00	12.45	9.08	0.06	1.89	0.99	C
Antibacterials	<i>Sulfadiazine</i>	250.28		C10H10N4O2S	0.39	6.99	2.01	0.35	-0.33	-0.51	N/A
Antibacterials	<i>Sulfamerazine</i>	264.30		C11H12N4O2S	0.52	6.99	2.00	0.48	-0.20	-0.5	N/A

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Antibacterials	Sulfamethoxazole	253.28		C10H11N3O3S	0.79	6.16	1.97	0.60	-0.11	-0.87	A
Antibacterials	Sulfamethoxypyridazine	280.30		C11H12N4O3S	0.47	6.84	2.02	0.41	-0.30	-0.59	N/A
Antibacterials	Sulfamoxole	267.30		C11H13N3O3S	0.59	6.81	1.94	0.53	-0.19	-0.61	N/A
Antibacterials	Sulfapyridine	249.29		C11H11N3O2S	1.01	6.24	2.14	0.84	0.12	-0.85	A
Antibacterials	Sulfathiazole	255.31		C9H9N3O2S2	0.98	6.93	2.04	0.93	0.24	-0.54	N/A
Antibacterials	Sulfisoxazole	267.30		C11H13N3O3S	0.73	5.80	2.17	0.39	-0.19	-0.94	A
Antibacterials	Tetracycline	444.44		C22H24N2O8	-3.49	3.26	9.25	-3.50	-4.28	-0.32	Z
Antibacterials	Trimethoprim	290.32		C14H18N4O3	1.28	17.33	7.16	0.27	1.23	0.93	N/C











Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	Log K _{ow}	Strongest acidic pK _a	Strongest basic pK _a	Log D _{ow} (pH=6)	Log D _{ow} (pH=8)	Charge (pH=7)	A,N,Z,C*
Anticoagulants	Warfarin	308.33		C19H16O4	2.74	5.56	--	2.17	0.45	-0.96	A
Antidiabetics	Metformin	129.17		C4H11N5	-0.92	19.17	12.33	-5.74	-5.37	2	C
Anti-histamines	Diphenhydramine	255.36		C17H21NO	3.65	--	8.87	0.87	2.73	0.99	C
Anti-hypertensives	3-(3,4-Dimethoxyphenyl)-2-methyl-6-methylaminohexane-3-carbonitrile (D617)	290.41		C17H26N2O2	2.96	--	10.54	-0.26	0.50	1	C
Anti-hypertensives	Enalapril	376.45		C20H28N2O5	0.59	3.67	5.20	-0.07	-1.22	-0.98	A
Anti-hypertensives	Verapamil	454.61		C27H38N2O4	5.04	--	9.68	1.76	3.36	1	C
Antimycotics	Carbendazim	191.19		C9H9N3O2	1.80	9.70	4.28	1.79	1.79	0	N
Antimycotics	Fluconazole	306.28		C13H12F2N6O	0.56	12.68	2.30	0.56	0.56	0	N
Antimycotics	Ketoconazole	531.43		C26H28Cl2N4O4	4.19	--	6.42	3.85	4.18	0.21	N/C










Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	Log K _{ow}	Strongest acidic pK _a	Strongest basic pK _a	Log D _{ow} (pH=6)	Log D _{ow} (pH=8)	Charge (pH=7)	A,N,Z,C*
Antimycotics	Propiconazole	342.22		C15H17Cl2N3O2	4.33	--	1.95	4.33	4.33	0	N
Antineoplastics	Cyclophosphamide	261.08		C7H15Cl2N2O2P	0.10	13.48	--	0.10	0.10	0	N
Antineoplastics	Flutamide	276.22		C11H11F3N2O3	3.27	12.81	--	3.27	3.27	0	Z
Antineoplastics	Hydroxytamoxifen	387.52		C26H29NO2	5.69	9.45	8.66	3.36	5.20	0.97	C
Antineoplastics	Ifosfamide	261.08		C7H15Cl2N2O2P	0.10	14.64	--	0.10	0.10	0	N
Antineoplastics	Tamoxifen	371.52		C26H29NO	6.35	--	8.76	3.66	5.52	0.98	C
Antiseptics	Triclosan	289.54		C12H7Cl3O2	4.98	7.68	--	4.97	4.50	-0.17	N/A
Antivirals	Oseltamivir	312.41		C16H28N2O4	1.16	14.03	9.26	-1.67	-0.11	0.99	C
Antivirals	Oseltamivir carboxylate	284.36		C14H24N2O4	-1.84	4.19	9.29	-1.84	-1.86	0	Z








Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Antivirals	Ritonavir	720.95		C37H48N6O5S2	5.22	13.68	2.84	5.22	5.22	0	N
Beta-agonists	Terbutaline	225.29		C12H19NO3	0.44	8.86	9.76	-1.70	-0.19	0.98	C
Beta-blockers	Atenolol	266.34		C14H22N2O3	0.43	14.08	9.67	-2.68	-1.24	1	C
Beta-blockers	Atenolol acid	267.33		C14H21NO4	-1.24	3.54	9.67	-1.24	-1.25	0	Z
Beta-blockers	Bisoprolol	325.45		C18H31NO4	2.20	14.09	9.67	-0.91	0.53	1	C
Beta-blockers	Metoprolol	267.37		C15H25NO3	1.76	14.09	9.67	-1.34	0.09	1	C
Beta-blockers	Propranolol	259.35		C16H21NO2	2.58	14.09	9.67	-0.52	0.92	1	C
Beta-blockers	Sotalol	272.36		C12H20N2O3S	-0.40	10.07	9.43	-3.04	-1.56	0.99	C
Calcium channel blockers	Amlodipine	408.88		C20H25CIN2O5	1.64	16.62	9.30	-1.21	0.33	0.99	C

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Contrast media	Amidotrizoic acid (diatrizoate)	613.92		C11H9I3N2O4	2.89	2.17	--	-0.46	-0.63	-1	A
Contrast media	Iothalamic acid	613.92		C11H9I3N2O4	2.73	2.13	--	-0.64	-0.80	-1	A
Contrast media	Iohexol	821.14		C19H26I3N3O9	-1.95	11.73	--	-1.95	-1.95	0	N
Contrast media	Iomeprol	777.09		C17H22I3N3O8	-1.45	11.73	--	-1.45	-1.45	0	N
Contrast media	Iopamidol	777.09		C17H22I3N3O8	-0.74	11.00	--	-0.74	-0.74	0	N
Contrast media	Iopromide	791.12		C18H24I3N3O8	-0.44	11.09	--	-0.44	-0.45	0	N
Contrast media	Ioxitalamic acid	643.94		C12H11I3N2O5	3.23	2.87	1.91	-1.17	-4.89	-0.94	A
Diuretics	Furosemide	330.74		C12H11ClN2O5S	1.75	4.25	--	0.00	-1.58	-1	A

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Diuretics	Hydrochlorothiazide	297.73		C7H8ClN3O4S2	-0.58	9.09	--	-0.58	-0.61	0	N
Gastrointestinal disorder drugs	Mebeverine	429.56		C25H35NO5	4.89	--	10.31	1.45	2.60	1	C
Hormones	17 α -ethynodiol (EE2)	296.41		C20H24O2	3.90	10.33	--	3.90	3.90	0	N
Hormones	17 β -estradiol (Estradiol/E2 β)	272.39		C18H24O2	3.75	10.33	--	3.75	3.74	0	N
Hormones	17 β -estradiol-acetate	314.43		C20H26O3	4.19	10.33	--	4.19	4.18	0	N
Hormones	Boldenone	286.42		C19H26O2	3.36	18.39	--	3.36	3.36	0	N
Hormones	Boldione	284.40		C19H24O2	3.93	18.39	--	3.93	3.93	0	N
Hormones	Cyproterone acetate	416.94		C24H29ClO4	3.64	17.83	--	3.64	3.64	0	N
Hormones	Dihydrotestosterone	290.45		C19H30O2	3.41	19.38	--	3.41	3.41	0	N
Hormones	Estriol (E3)	288.39		C18H24O3	2.67	10.33	--	2.67	2.67	0	N

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Hormones	<i>Estrone (E1)</i>	270.37		C18H22O2	4.31	10.33	--	4.31	4.31	0	N
Hormones	<i>Etiocloanolone</i>	290.45		C19H30O2	3.77	18.30	--	3.77	3.77	0	N
Hormones	<i>Nandrolone</i>	274.40		C18H26O2	3.07	18.25	--	3.07	3.07	0	N
Hormones	<i>Norethindrone</i>	298.43		C20H26O2	3.22	17.59	--	3.22	3.22	0	N
Hormones	<i>Progesterone</i>	314.47		C21H30O2	4.15	18.47	--	4.15	4.15	0	N
Hormones	<i>Testosterone</i>	288.43		C19H28O2	3.37	18.52	--	3.37	3.37	0	N
Lipid regulators	<i>Bezafibrate</i>	361.82		C19H20ClNO4	3.99	3.83	--	1.83	0.55	-1	A
Lipid regulators	<i>Clofibrate acid</i>	214.65		C10H11ClO3	2.90	3.37	--	0.32	-0.60	-1	A
Lipid regulators	<i>Fenofibric acid</i>	318.75		C17H15ClO4	4.36	3.10	--	1.55	0.85	-1	A
Lipid regulators	<i>Gemfibrozil</i>	250.34		C15H22O3	4.39	4.42	--	2.80	1.14	-1	A









Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Lipid regulators	Simvastatin	418.57		C25H38O5	4.46	14.91	--	4.46	4.46	0	N
Non-ionic surfactants	4-tert-octylphenol	206.33		C14H22O	4.69	10.23	--	4.69	4.69	0	N
Non-ionic surfactants	Nonylphenol	220.36		C15H24O	5.74	10.30	--	5.74	5.74	0	N
Other	4-Methylbenzotriazole	133.15		C7H7N3	1.81	8.93	0.78	1.81	1.77	0	N
Other	4-n-nonylphenol	220.36		C15H24O	5.74	10.31	--	5.74	5.74	0	N
Other	4-tert-butylphenol	150.22		C10H14O	3.21	10.24	--	3.21	3.21	0	N
Other	5-Methylbenzotriazole	133.15		C7H7N3	1.81	8.86	1.02	1.81	1.76	0	N
Other	Benzalkonium chloride	170.66		C9H13ClN	1.68	17.90	--	1.68	1.68	--	--
Other	Benzothiazole	135.18		C7H5NS	2.11	--	2.28	2.11	2.11	0	N









Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Other	Benzotriazole	119.13		C6H5N3	1.30	8.63	0.60	1.30	1.21	0	N
Other	Bisphenol A	228.29		C15H16O2	4.04	9.78	--	4.04	4.04	0	N
Other	Bisphenol A diglycidyl ether	340.42		C21H24O4	4.02	--	--	4.02	4.02	0	N
Other	Bisphenol F diglycidyl ether	312.37		C19H20O4	3.43	--	--	3.43	3.43	0	N
Other	Irgarol (Cybutryne)	253.37		C11H19N5S	2.99	14.13	6.68	2.24	2.97	0.32	N/C
Other	Methylbenzotriazole	159.19		C9H9N3	2.44	8.95	0.10	2.44	2.40	0	N
Other	Octylphenol	206.33		C14H22O	5.30	10.31	--	5.30	5.29	0	N
Other	Perfluorooctanoate (PFOA)	413.06		C8F15O2	5.11	--	--	1.58	1.58	-1	A









Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Other	<i>Perfluorooctane sulfonate (PFOS)</i>	499.12		C8F17O3S	5.43	--	--	3.05	3.05	-1	A
Other	<i>tris(2-carboxyethyl) phosphine (TCEP)</i>	250.19		C9H15O6P	-1.24	3.22	8.94	-7.30	-10.78	-2.01	A
Other	<i>tris(1,3-dichloroisopropyl) phosphate (TDCPP)</i>	430.89		C9H15Cl6O4P	4.28	--	--	4.28	4.28	0	N
Pesticides	<i>Atrazine</i>	215.69		C8H14N5	2.20	14.48	4.20	2.19	2.20	0	N
Pesticides	<i>Diuron</i>	233.09		C9H10Cl2N2O	2.53	13.18	--	2.53	2.53	0	N
Pesticides	<i>Fenoprop</i>	269.50		C9H7Cl3O3	3.67	2.70	--	0.57	0.15	-1	A
Pesticides	<i>Isoproturon</i>	206.29		C12H18N2O	2.57	13.79	--	2.57	2.57	0	N
Pesticides	<i>Mecoprop</i>	214.65		C10H11ClO3	2.98	3.47	--	0.49	-0.51	-1	A







Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Pesticides	<i>N,N-diethyl-m-toluamide (DEET)</i>	191.27		C12H17NO	2.50	--	--	2.50	2.50	0	N
Pesticides	<i>Pentachlorophenol</i>	266.32		C6HCl5O	4.69	4.98	--	3.67	2.68	-0.99	A
Pesticides	<i>Terbutryn</i>	241.36		C10H19N5S	2.88	14.31	6.72	2.11	2.85	0.34	N/C
Psychiatric drugs	<i>10,11-Dihydro-10,11-dihydroxy carbamazepine</i>	270.29		C15H14N2O3	0.81	12.84	--	0.81	0.81	0	N
Psychiatric drugs	<i>Amitriptyline</i>	277.41		C20H23N	4.81	--	9.76	1.50	3.05	1	C
Psychiatric drugs	<i>Carbamazepine</i>	236.27		C15H12N2O	2.77	15.96	--	2.77	2.77	0	N
Psychiatric drugs	<i>Citalopram</i>	324.40		C20H21FN2O	3.76	--	9.78	0.44	1.98	1	C
Psychiatric drugs	<i>Diazepam</i>	284.74		C16H13ClN2O	3.08	--	2.92	3.08	3.08	0	N


Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	Log K _{ow}	Strongest acidic pK _a	Strongest basic pK _a	Log D _{ow} (pH=6)	Log D _{ow} (pH=8)	Charge (pH=7)	A,N,Z,C*
Psychiatric drugs	Dilantin	252.27		C15H12N2O2	2.15	8.49	--	2.15	2.03	0	N
Psychiatric drugs	Fluoxetine	309.33		C17H18F3NO	4.17	--	9.80	1.04	2.38	1	C
Psychiatric drugs	Gabapentin	171.24		C9H17NO2	-1.27	4.63	9.91	-1.29	-1.28	0.01	Z
Psychiatric drugs	Levetiracetam	170.21		C8H14N2O2	-0.59	16.09	--	-0.59	-0.59	0	N
Psychiatric drugs	N,N-didesvenlafaxine	249.35		C15H23NO2	1.92	14.42	9.43	-0.96	0.49	1	C
Psychiatric drugs	Oxazepam	286.72		C15H11ClN2O2	2.92	10.61	--	2.92	2.92	0	N
Psychiatric drugs	Primidone	218.26		C12H14N2O2	1.12	11.50	--	1.12	1.12	0	N
Psychiatric drugs	Risperidone	410.49		C23H27FN4O2	2.63	--	8.76	-0.08	1.80	0.99	C

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Psychiatric drugs	Sertraline	306.23		C17H17Cl2N	5.15	--	9.56	2.08	3.58	1	C
Psychiatric drugs	Thioridazine	370.57		C21H26N2S2	5.47	--	8.93	2.64	4.49	0.99	C
Psychiatric drugs	Venlafaxine	277.41		C17H27NO2	2.74	14.42	8.91	-0.07	1.78	0.99	C
Receptor antagonists	Eprosartan	424.52		C23H24N2O4S	3.75	3.47	6.67	2.02	-0.78	-1.68	A
Receptor antagonists	Irbesartan	428.54		C25H28N6O	5.39	5.85	4.12	5.13	4.04	-0.93	A
Receptor antagonists	Losartan	422.92		C22H23ClN6O	5.00	5.85	3.85	4.72	3.63	-0.93	A
Receptor antagonists	Ramipril	416.52		C23H32N2O5	1.47	3.75	5.20	0.84	-0.36	-0.98	A
Receptor antagonists	Ranitidine	314.40		C13H22N4O3S	0.99	--	7.80	-0.80	0.78	0.86	Z

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Receptor antagonists	Valsartan	435.53		C24H29N5O3	5.27	4.35	--	3.27	0.50	-1.93	A
Receptor antagonists	Valsartan acid	266.26		C14H10N4O2	3.18	4.03	--	0.85	-1.71	-1.93	A
Stimulant	Caffeine	194.19		C8H10N4O2	-0.55	--	--	-0.55	-0.55	0	N
Stimulant	Ritalinic acid	219.28		C13H17NO2	-0.36	3.73	10.08	-0.36	-0.37	0	Z
Stimulant	Theophylline	180.17		C7H8N4O2	-0.77	7.82	--	-0.78	-1.11	-0.13	N/A
Sweetener	Aspartame	294.31		C14H18N2O5	-2.22	3.53	8.53	-2.22	-2.32	-0.03	Z
Synthetic musks	Celestolide	244.38		C17H24O	4.67	16.18	--	4.67	4.67	0	N
Synthetic musks	Galaxolide	258.41		C18H26O	4.72	--	--	4.72	4.72	0	N

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Synthetic musks	Tonalide	258.41		C18H26O	4.96	16.30	--	4.96	4.96	0	N
Urological drug	Finasteride	372.55		C23H36N2O2	3.07	14.53	0.33	3.07	3.07	0	N
UV filters	2-phenyl-5-benzimidazolesulfonic acid	274.29		C13H10N2O3S	-0.14	--	4.55	0.08	0.09	-1	A
UV filters	Benzophenone-3	228.25		C14H12O3	3.62	7.07	--	3.59	2.67	-0.46	A
UV filters	Butyl methoxydibenzoylmethane	310.39		C20H22O3	4.56	9.92	--	4.56	4.56	0	N
UV filters	Oxybenzone	228.25		C14H12O3	3.62	7.07	--	3.59	2.67	-0.46	N/A
Veterinary drugs	Enrofloxacin	359.40		C19H22FN3O3	0.51	5.55	7.24	0.51	-0.14	-0.3	Z
Veterinary drugs	Marbofloxacin	362.36		C17H19FN4O4	-0.61	5.28	6.69	-0.61	-1.74	-0.63	Z
Veterinary drugs	Monensin	670.88		C36H62O11	4.82	4.24	--	3.05	1.49	-1	A

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Veterinary drugs	Sarafloxacin	385.37		C20H17F2N3O3	0.52	5.55	8.76	0.43	0.47	0.05	Z
Veterinary drugs	Sulfachloropyridazine	284.72		C10H9ClN4O2S	0.85	6.60	2.02	0.77	0.02	-0.72	N/A
Veterinary drugs	Sulfaclozine	284.72		C10H9ClN4O2S	0.62	6.49	1.90	0.51	-0.24	-0.76	N/A
Veterinary drugs	Sulfadimethoxine	310.33		C12H14N4O4S	1.26	6.91	1.99	1.22	0.52	-0.55	N/A
Veterinary drugs	Sulfadimidine	278.33		C12H14N4O2S	0.65	6.99	2.00	0.61	-0.06	-0.5	N/A
Veterinary drugs	Sulfadoxine	310.33		C12H14N4O4S	0.58	6.12	3.44	0.37	-0.32	-0.88	A
Veterinary drugs	Sulfamonomethoxine	280.30		C11H12N4O3S	0.74	7.15	3.53	0.71	0.09	-0.41	N/A
Veterinary drugs	Trenbolone	270.37		C18H22O2	2.25	18.40	--	2.25	2.25	0	N

Class	Compound	Molecular Weight (g/mol)	Structure	Molecular formula	$\log K_{ow}$	Strongest acidic pKa	Strongest basic pKa	$\log D_{ow}$ (pH=6)	$\log D_{ow}$ (pH=8)	Charge (pH=7)	A,N,Z,C*
Veterinary drugs	Tylosin	916.11		C46H77NO17	2.32	12.45	8.43	-0.08	1.75	0.96	C

*A=anionic, N=neutral, Z=zwitterionic, C=cationic (at pH=7)

Source: J Chem for Office was used for calculating the physical and chemical properties, JChem for Office 20.11.0, ChemAxon (<https://www.chemaxon.com>).

Last access on 4 February 2021

Table S2: Main characteristics of the peer reviewed studies included in this survey (See Excel file)

Table S3: Compounds for which the removal in MBR is equal or higher than the removal achieved in MBR+PAC, (corresponding reference in the first column). Removal efficiencies are considered the same if the difference between the two percentages is less than 2. The reported value is the highest one.

Paper	<i>Compounds</i> ($\eta_{MBR} = \eta_{MBR+PAC}$)	<i>Compounds</i> ($\eta_{MBR} > \eta_{MBR+PAC}$)
(Alvarino et al., 2016)	ibuprofen (~98%); sulfamethoxazole (~93%)	--
(Alvarino et al., 2017)	17- α ethinylestradiol (EE2) (~96% (UF)); ibuprofen (~93% (MF), ~99.9% (UF)); diclofenac (~63% (UF)); estrone (E1) (~99% (MF), ~99% (UF)); naproxen (~94% (MF)); roxithromycin (~99.9% (UF)); sulfamethoxazole (~82% (MF))	17- α ethinylestradiol (EE2) (96%>87% (MF), 96%>91% (MF), 96%>89% (UF), 96%>84% (UF)); estrone (E1) (99%>96% (UF), 99%>92% (UF)); naproxen (94%>91% (MF), 94%>90% (MF)); sulfamethoxazole (80%>73% (MF), 74%>68% (UF))
(Asif et al., 2020)	oxytetracycline (~99.9%); paracetamol (~99.9%); salicylic acid (99.9%)	--
(Echevarría et al., 2019)	atenolol (~97%); nonylphenol (~95%); octylphenol (89%); paracetamol (99%)	sulfamethoxazole (60%>54%)
(Li et al., 2011)	--	sulfamethoxazole (63%>40%); carbamazepine (12%>–90%)
(Nguyen et al., 2013a)	17 β -estradiol (Estradiol/E2 β) (~99.9%); 17 β -estradiol-acetate (~99%); 4-n-nonylphenol (97%); 4-tert-butylphenol (~95%); 4-tert-octylphenol (~98%); estriol (~98%); estrone (~97%); gemfibrozil (~99%); ibuprofen (~96%); salicylic acid (98%); triclosan (~99%)	estriol (E3) (97%>86%); paracetamol (87%>81%); salicylic acid (98%>93%)
(Remy et al., 2012)	caffeine (99.9%)	--

Table S4: Compounds for which the removal in MBR is equal or higher than the removal achieved in MBR→GAC, (corresponding reference in the first column). Removal efficiencies are considered the same if the difference between the two percentages is less than 2. The reported value is the highest one.

Reference	<i>Compounds</i> $(\eta_{MBR} = \eta_{MBR \rightarrow GAC})$	<i>Compounds</i> $(\eta_{MBR} > \eta_{MBR+PAC})$
(Nguyen et al., 2013a)	17 β -estradiol (Estradiol / E2 β) (~99.9%); 17 β -estradiol-acetate (~99.9%); 4-n-nonylphenol (~99%); 4-tert-octylphenol (~99%); estriol (E3) (~99%); gemfibrozil (~99.9%); paracetamol (87%); salicylic acid (~98%); triclosan (~99.9%)	--
(Nguyen et al., 2013b)	17 α ethinylestradiol (EE2) (~96%); 17 β -estradiol (Estradiol / E2 β) (99.9%); 17 β -estradiol-acetate (~99.9%); 4-n-nonylphenol (~99.9%); 4-tert-octylphenol (~99.9%); bisphenol A (99.9%); estriol (E3) (~99.9%); estrone (E1) (~99.9%); fenoprop (32%); gemfibrozil (~99.9%); ibuprofen (~99.9%); paracetamol (96%); primidone (99.9%); salicylic acid (~99.9%); triclosan (99.9%)	--




Figure S2. Removal efficiencies for the investigated compound in MBR+PAC with submerged and side stream membrane unit (see Table 1 of the manuscript) in the studies included in the review, reported in the legend. Data from: (Alvarino et al., 2017, 2016; Asif et al., 2020; Echevarría et al., 2019; Li et al., 2011; Nguyen et al., 2013a; Remy et al., 2012; Serrano et al., 2011; Yang et al., 2012; Yu et al., 2014)

Release of the compounds are not reported in the graph. Release data refer to carbamazepine, according to (Li et al., 2011).




Figure S3. Removal efficiencies for the investigated MPs in GAC column acting as a post treatment (polishing) grouped according to the Authors. Plant configurations in which GAC is included are in brackets (as reported in Table 1 of the manuscript). Data from: (Baresel et al., 2019; Grover et al., 2011; Itzel et al., 2018; Langenhoff et al., 2013; Nguyen et al., 2013b, 2012; Paredes et al., 2018; Paulus et al., 2019; Sbardella et al., 2018)




Figure S4. Concentration in the effluent of a PAC/GAC unit acting as a PT (part 1). Data from: (Baresel et al., 2019; Grover et al., 2011; Itzel et al., 2018; Kovalova et al., 2013; Löwenberg et al., 2014; Margot et al., 2013; Nguyen et al., 2013b, 2012; Paulus et al., 2019). It is important to remark that the investigated configurations in (Itzel et al., 2018) and (Paulus et al., 2019) include an ozonation step between the MBR and the GAC unit and the reported values of removal efficiencies refer to the whole treatment train. Compounds in light pink refer to only PAC and in light grey to only GAC. Those not highlighted refer to both PAC and GAC units.




Figure S5. Concentration in the effluent of a PAC/GAC unit acting as a PT (part 2). Data from: (Baresel et al., 2019; Grover et al., 2011; Itzel et al., 2018; Kovalova et al., 2013; Löwenberg et al., 2014; Margot et al., 2013; Nguyen et al., 2013b, 2012; Paulus et al., 2019). It is important to remark that the investigated configurations in (Itzel et al., 2018) and (Paulus et al., 2019) include an ozonation step between the MBR and the GAC unit and the reported values of removal efficiencies refer to the whole treatment train. Compounds in light pink refer to only PAC and in light grey to only GAC. Those not highlighted refer to both PAC and GAC units




Figure S6. Concentration in the effluent of a PAC/GAC unit acting as a PT. Data from: (Baresel et al., 2019; Grover et al., 2011; Itzel et al., 2018; Kovalova et al., 2013; Löwenberg et al., 2014; Margot et al., 2013; Nguyen et al., 2013b, 2012; Paulus et al., 2019). It is important to remark that the investigated configurations in (Itzel et al., 2018) and (Paulus et al., 2019) include an ozonation step between the MBR and the GAC unit and the reported values of removal efficiencies refer to the whole treatment train.




Figure S7. Removal efficiencies in PAC units acting as a PT for the compounds grouped according to their charge and in descending order according to $\text{Log } D_{ow}$. Data from: (Kovalova et al., 2013; Löwenberg et al., 2014; Margot et al., 2013)

References

(the studies included in the quantitative analysis of MP removal by enhanced MBR are shown in bold)

- Abegglen, C., Joss, A., Boehler, M., Buetzer, S., Siegrist, H., 2009. Reducing the natural color of membrane bioreactor permeate with activated carbon or ozone. *Water Sci. Technol.* 60, 155–165.
<https://doi.org/10.2166/wst.2009.331>
- Alvarino, T., Komesli, O., Suarez, S., Lema, J.M., Omil, F., 2016. The potential of the innovative SeMPAC process for enhancing the removal of recalcitrant organic micropollutants. *J. Hazard. Mater.* 308, 29–36.**
<https://doi.org/10.1016/j.jhazmat.2016.01.040>
- Alvarino, T., Torregrosa, N., Omil, F., Lema, J.M., Suarez, S., 2017. Assessing the feasibility of two hybrid MBR systems using PAC for removing macro and micropollutants. *J. Environ. Manage.* 203, 831–837.
<https://doi.org/10.1016/j.jenvman.2016.03.023>
- Asif, M.B., Ren, B., Li, C., Maqbool, T., Zhang, X., Zhang, Z., 2020. Powdered activated carbon – Membrane bioreactor (PAC-MBR): Impacts of high PAC concentration on micropollutant removal and microbial communities. *Sci. Total Environ.* 745, 141090. <https://doi.org/10.1016/j.scitotenv.2020.141090>
- Baresel, C., Harding, M., Fang, J., 2019. Ultrafiltration/granulated active carbon-biofilter: Efficient removal of a broad range of micropollutants. *Appl. Sci.* 9. <https://doi.org/10.3390/app9040710>
- Cho, Y.-H., Sibag, M.L., Eusebio, R.C., Kim, H.-S., 2011. Effect of organic loading on the performance of MBR for advanced treatment and water reuse. *Desalin. Water Treat.* 33, 224–230.
<https://doi.org/10.5004/dwt.2011.2642>
- Echevarría, C., Valderrama, C., Cortina, J.L.L., Martín, I., Arnaldos, M., Bernat, X., De la Cal, A., Boleda, M.R.R., Vega, A., Teuler, A., Castellví, E., 2019. Techno-economic evaluation and comparison of PAC-MBR and ozonation-UV revamping for organic micro-pollutants removal from urban reclaimed wastewater. *Sci. Total Environ.* 671, 288–298. <https://doi.org/10.1016/j.scitotenv.2019.03.365>
- Gao, Y., Ma, D., Yue, Q., Gao, B., Huang, X., 2016. Effect of powdered activated carbon (PAC) on MBR performance and effluent trihalomethane formation: At the initial stage of PAC addition. *Bioresour. Technol.* 216, 838–844.
<https://doi.org/10.1016/j.biortech.2016.06.030>
- Gkotsis, P., Zouboulis, A., Mitrakas, M., 2020. Using additives for fouling control in a lab-scale MBR; comparing the anti-fouling potential of coagulants, PAC and bio-film carriers. *Membranes (Basel.)* 10.
<https://doi.org/10.3390/membranes10030042>
- Grover, D.P., Zhou, J.L., Frickers, P.E., Readman, J.W., 2011. Improved removal of estrogenic and pharmaceutical compounds in sewage effluent by full scale granular activated carbon: Impact on receiving river water. *J. Hazard. Mater.* 185, 1005–1011.** <https://doi.org/10.1016/j.jhazmat.2010.10.005>
- Guo, W., Vigneswaran, S., Ngo, H.-H., Xing, W., Goteti, P., 2008. Comparison of the performance of submerged membrane bioreactor (SMBR) and submerged membrane adsorption bioreactor (SMABR). *Bioresour. Technol.* 99, 1012–1017. <https://doi.org/10.1016/j.biortech.2007.03.012>
- Itzel, F., Jewell, K.S., Leonhardt, J., Gehrmann, L., Nielsen, U., Ternes, T.A., Schmidt, T.C., Tuerk, J., 2018. Comprehensive analysis of antagonistic endocrine activity during ozone treatment of hospital wastewater. *Sci. Total Environ.* 624, 1443–1454.** <https://doi.org/10.1016/j.scitotenv.2017.12.181>
- Iversen, V., Koseoglu, H., Yigit, N.O., Drews, A., Kitis, M., Lesjean, B., Kraume, M., 2009a. Impacts of membrane flux enhancers on activated sludge respiration and nutrient removal in MBRs. *Water Res.* 43, 822–830.
<https://doi.org/10.1016/j.watres.2008.11.022>
- Iversen, V., Mehrez, R., Horng, R.Y., Chen, C.H., Meng, F., Drews, A., Lesjean, B., Ernst, M., Jekel, M., Kraume, M., 2009b. Fouling mitigation through flocculants and adsorbents addition in membrane bioreactors: Comparing lab and pilot studies. *J. Memb. Sci.* 345, 21–30. <https://doi.org/10.1016/j.memsci.2009.08.014>
- Jamal Khan, S., Visvanathan, C., Jegatheesan, V., 2012. Effect of powdered activated carbon (PAC) and cationic polymer on biofouling mitigation in hybrid MBRs. *Bioresour. Technol.* 113, 165–168.
<https://doi.org/10.1016/j.biortech.2011.12.107>

- Johir, M.A., Shanmuganathan, S., Vigneswaran, S., Kandasamy, J., 2013. Performance of submerged membrane bioreactor (SMBR) with and without the addition of the different particle sizes of GAC as suspended medium. *Bioresour. Technol.* 141, 13–18. <https://doi.org/10.1016/j.biortech.2013.03.032>
- Johir, M.A.H., Aryal, R., Vigneswaran, S., Kandasamy, J., Grasmick, A., 2011. Influence of supporting media in suspension on membrane fouling reduction in submerged membrane bioreactor (SMBR). *J. Memb. Sci.* 374, 121–128. <https://doi.org/10.1016/j.memsci.2011.03.023>
- Johir, M.A.H., Shim, W.G., Pradhan, M., Vigneswaran, S., Kandasamy, J., 2016. Benefit of adding adsorbent in submerged membrane microfiltration treatment of wastewater. *Desalin. Water Treat.* 57, 20683–20693. <https://doi.org/10.1080/19443994.2015.1110049>
- Kovalova, L., Siegrist, H., von Gunten, U., Eugster, J., Hagenbuch, M., Wittmer, A., Moser, R., Mc Ardell, C.S., 2013. Elimination of Micropollutants during Post-Treatment of Hospital Wastewater with Powdered Activated Carbon, Ozone, and UV. *Environ. Sci. Technol.* 47, 7899–7908. <https://doi.org/10.1021/es400708w>**
- Langenhoff, A., Inderfurth, N., Veuskens, T., Schraa, G., Blokland, M., Kujawa-Roeleveld, K., Rijnaarts, H., 2013. Microbial removal of the pharmaceutical compounds ibuprofen and diclofenac from wastewater. *Biomed Res. Int.* 2013. <https://doi.org/10.1155/2013/325806>**
- Lee, J.J., Woo, Y.C., Kang, J.-S., Kang, C.Y., Kim, H.-S., 2016. Effect of various pretreatments on the performance of nanofiltration for wastewater reuse. *Desalin. Water Treat.* 57, 7522–7530. <https://doi.org/10.1080/19443994.2015.1030116>
- Lee, S., Lee, J.-W., Kim, S., Park, P.-K., Kim, J.-H., Lee, C.-H., 2009. Removal of 17 β -estradiol by powdered activated carbon-Microfiltration hybrid process: The effect of PAC deposition on membrane surface. *J. Memb. Sci.* 326, 84–91. <https://doi.org/10.1016/j.memsci.2008.09.031>
- Lee, W.-N., Yeon, K.-M., Hwang, B.-K., Lee, C.-H., Chang, I.-S., 2010. Effect of PAC addition on the physicochemical characteristics of bio-cake in a membrane bioreactor. *Sep. Sci. Technol.* 45, 896–903. <https://doi.org/10.1080/01496391003666999>
- Lei, Z., Yang, S., Li, X., Wen, W., Huang, X., Yang, Y., Wang, X., Li, Y.-Y., Sano, D., Chen, R., 2019. Revisiting the effects of powdered activated carbon on membrane fouling mitigation in an anaerobic membrane bioreactor by evaluating long-term impacts on the surface layer. *Water Res.* 167. <https://doi.org/10.1016/j.watres.2019.115137>
- Li, X., Hai, F.I., Nghiem, L.D., 2011. Simultaneous activated carbon adsorption within a membrane bioreactor for an enhanced micropollutant removal. *Bioresour. Technol.* 102, 5319–5324. <https://doi.org/10.1016/j.biortech.2010.11.070>**
- Lin, H., Wang, F., Ding, L., Hong, H., Chen, J., Lu, X., 2011. Enhanced performance of a submerged membrane bioreactor with powdered activated carbon addition for municipal secondary effluent treatment. *J. Hazard. Mater.* 192, 1509–1514. <https://doi.org/10.1016/j.jhazmat.2011.06.071>
- Lipp, P., Groß, H.J.H.-J., Tiehm, A., 2012. Improved elimination of organic micropollutants by a process combination of membrane bioreactor (MBR) and powdered activated carbon (PAC). *Desalin. Water Treat.* 42, 65–72. <https://doi.org/10.1080/19443994.2012.683137>**
- Löwenberg, J., Zenker, A., Baggenstos, M., Koch, G., Kazner, C., Wintgens, T., 2014. Comparison of two PAC/UF processes for the removal of micropollutants from wastewater treatment plant effluent: Process performance and removal efficiency. *Water Res.* 56, 26–36. <https://doi.org/10.1016/j.watres.2014.02.038>**
- Ma, D., Gao, B., Xia, C., Wang, Y., Yue, Q., Li, Q., 2014a. Effects of sludge retention times on reactivity of effluent dissolved organic matter for trihalomethane formation in hybrid powdered activated carbon membrane bioreactors. *Bioresour. Technol.* 166, 381–388. <https://doi.org/10.1016/j.biortech.2014.05.082>
- Ma, D., Gao, Y., Gao, B., Wang, Y., Yue, Q., Li, Q., 2014b. Impacts of powdered activated carbon addition on trihalomethane formation reactivity of dissolved organic matter in membrane bioreactor effluent. *Chemosphere* 117, 338–344. <https://doi.org/10.1016/j.chemosphere.2014.07.070>
- Margot, J., Kienle, C., Magnet, A., Weil, M., Rossi, L., de Alencastro, L.F., Abegglen, C., Thonney, D., Chèvre, N., Schärer, M., Barry, D.A., 2013. Treatment of micropollutants in municipal wastewater: Ozone or powdered**

activated carbon? *Sci. Total Environ.* 461–462, 480–498. <https://doi.org/10.1016/j.scitotenv.2013.05.034>

Mohamadi, S., Hazrati, H., Shayegan, J., 2019. Influence of a new method of applying adsorbents on membrane fouling in MBR systems. *Water Environ. J.* 1–12. <https://doi.org/10.1111/wej.12532>

Navaratna, D., Shu, L., Jegatheesan, V., 2016. Evaluation of herbicide (persistent pollutant) removal mechanisms through hybrid membrane bioreactors. *Bioresour. Technol.* 200, 795–803. <https://doi.org/10.1016/j.biortech.2015.10.041>

Ng, C.A., Sun, D., Bashir, M.J.K., Wai, S.H., Wong, L.Y., Nisar, H., Wu, B., Fane, A.G., 2013. Optimization of membrane bioreactors by the addition of powdered activated carbon. *Bioresour. Technol.* 138, 38–47. <https://doi.org/10.1016/j.biortech.2013.03.129>

Nguyen, L.N., Hai, F.I., Kang, J., Nghiem, L.D., Price, W.E., Guo, W., Ngo, H.H., Tung, K.-L.K.L., 2013a. Comparison between sequential and simultaneous application of activated carbon with membrane bioreactor for trace organic contaminant removal. *Bioresour. Technol.* 130, 412–417. <https://doi.org/10.1016/j.biortech.2012.11.131>

Nguyen, L.N., Hai, F.I., Kang, J., Price, W.E., Nghiem, L.D., 2013b. Coupling granular activated carbon adsorption with membrane bioreactor treatment for trace organic contaminant removal: Breakthrough behaviour of persistent and hydrophilic compounds. *J. Environ. Manage.* 119, 173–181. <https://doi.org/10.1016/j.jenvman.2013.01.037>

Nguyen, L.N., Hai, F.I., Kang, J., Price, W.E., Nghiem, L.D., 2012. Removal of trace organic contaminants by a membrane bioreactor–granular activated carbon (MBR–GAC) system. *Bioresour. Technol.* 113, 169–173. <https://doi.org/10.1016/j.biortech.2011.10.051>

Nguyen, L.N., Hai, F.I., Nghiem, L.D., Kang, J., Price, W.E., Park, C., Yamamoto, K., 2014. Enhancement of removal of trace organic contaminants by powdered activated carbon dosing into membrane bioreactors. *J. Taiwan Inst. Chem. Eng.* 45, 571–578. <https://doi.org/10.1016/j.jtice.2013.05.021>

Nielsen, U., Hastrup, C., Klausen, M.M., Pedersen, B.M., Kristensen, G.H., Jansen, J.L.C., Bak, S.N., Tuerk, J., 2013. Removal of APIs and bacteria from hospital wastewater by MBR plus O₃, O₃ + H₂O₂, PAC or ClO₂. *Water Sci. Technol.* 67, 854–862. <https://doi.org/10.2166/wst.2012.645>

Pan, Z., Zhang, C., Huang, B., 2016. Using adsorbent made from sewage sludge to enhance wastewater treatment and control fouling in a membrane bioreactor. *Desalin. Water Treat.* 57, 9070–9081. <https://doi.org/10.1080/19443994.2015.1029008>

Paredes, L., Alfonsin, C., Allegue, T., Omil, F., Carballa, M., 2018. Integrating granular activated carbon in the post-treatment of membrane and settler effluents to improve organic micropollutants removal. *Chem. Eng. J.* 345, 79–86. <https://doi.org/10.1016/j.cej.2018.03.120>

Paulus, G.K., Hornstra, L.M., Alygizakis, N., Slobodnik, J., Thomaidis, N., Medema, G., 2019. The impact of on-site hospital wastewater treatment on the downstream communal wastewater system in terms of antibiotics and antibiotic resistance genes. *Int. J. Hyg. Environ. Health* 222, 635–644. <https://doi.org/10.1016/j.ijheh.2019.01.004>

Plakas, K. V., Karabelas, A.J., Georgiadis, A.A., 2016. Sustainability assessment of tertiary wastewater treatment technologies: A multi-criteria analysis. *Water Sci. Technol.* 73, 1532–1540. <https://doi.org/10.2166/wst.2015.630>

Remy, M., Potier, V., Temmink, H., Rulkens, W., 2010. Why low powdered activated carbon addition reduces membrane fouling in MBRs. *Water Res.* 44, 861–867. <https://doi.org/10.1016/j.watres.2009.09.046>

Remy, M., Temmink, H., Rulkens, W., 2012. Effect of low dosages of powdered activated carbon on membrane bioreactor performance. *Water Sci. Technol.* 65, 954–961. <https://doi.org/10.2166/wst.2012.942>

Sbardella, L., Comas, J., Fenu, A., Rodriguez-Roda, I., Weemaes, M., 2018. Advanced biological activated carbon filter for removing pharmaceutically active compounds from treated wastewater. *Sci. Total Environ.* 636, 519–529. <https://doi.org/10.1016/j.scitotenv.2018.04.214>

Serrano, D., Suárez, S., Lema, J.M., Omil, F., 2011. Removal of persistent pharmaceutical micropollutants from

sewage by addition of PAC in a sequential membrane bioreactor. *Water Res.* **45**, 5323–5333.
<https://doi.org/10.1016/j.watres.2011.07.037>

Torretta, V., Urbini, G., Raboni, M., Copelli, S., Viotti, P., Luciano, A., Mancini, G., 2013. Effect of powdered activated carbon to reduce fouling in membrane bioreactors: A sustainable solution. Case study. *Sustain.* **5**, 1501–1509.
<https://doi.org/10.3390/su5041501>

Wang, F., Gao, B., Ma, D., Li, R., Sun, S., Yue, Q., Wang, Y., Li, Q., 2016. Effects of operating conditions on trihalomethanes formation and speciation during chloramination in reclaimed water. *Environ. Sci. Pollut. Res.* **23**, 1576–1583. <https://doi.org/10.1007/s11356-015-5409-3>

Wei, C.-H.C.H., Hoppe-Jones, C., Amy, G., Leiknes, T.O., Wang, N., HoppeJones, C., Leiknes, T.O., Amy, G., Fang, Q., Hu, X., Rong, H., Hoppe-Jones, C., Amy, G., Leiknes, T.O., 2016. Organic micro-pollutants' removal via anaerobic membrane bioreactor with ultrafiltration and nanofiltration. *J. Water Reuse Desalin.* **6**, 362–370.
<https://doi.org/10.2166/wrd.2015.138>

Wong, L.Y., Ng, C.A., Bashir, M.J.K.K., Cheah, C.K., Khoo, K.L., Ching, Y.C., 2016. Membrane bioreactor performance improvement by adding adsorbent and coagulant: a comparative study. *Desalin. Water Treat.* **57**, 13433–13439.
<https://doi.org/10.1080/19443994.2015.1060900>

Woo, Y.C., Lee, J.J., Jeong, A., Song, J., Choi, Y., Kim, H.S.H.-S., 2020. Removal of nitrogen by a sulfur-based carrier with powdered activated carbon (PAC) for denitrification in membrane bioreactor (MBR). *J. Water Process Eng.* **34**, 101149. <https://doi.org/10.1016/j.jwpe.2020.101149>

Woo, Y.C., Lee, J.J., Shim, W.-G.W.G., Shon, H.K., Tijing, L.D., Yao, M., Kim, H.S.H.-S., 2016. Effect of powdered activated carbon on integrated submerged membrane bioreactor-nanofiltration process for wastewater reclamation. *Bioresour. Technol.* **210**, 18–25. <https://doi.org/10.1016/j.biortech.2016.02.023>

Xiao, Y., Yaohari, H., De Araujo, C., Sze, C.C., Stuckey, D.C., 2017. Removal of selected pharmaceuticals in an anaerobic membrane bioreactor (AnMBR) with/without powdered activated carbon (PAC). *Chem. Eng. J.* **321**, 335–345.
<https://doi.org/10.1016/j.cej.2017.03.118>

Yang, S., Zhang, Q., Lei, Z., Wen, W., Huang, X., Chen, R., 2019. Comparing powdered and granular activated carbon addition on membrane fouling control through evaluating the impacts on mixed liquor and cake layer properties in anaerobic membrane bioreactors. *Bioresour. Technol.* **294**. <https://doi.org/10.1016/j.biortech.2019.122137>

Yang, W., Paetkau, M., Cicek, N., 2010. Improving the performance of membrane bioreactors by powdered activated carbon dosing with cost considerations. *Water Sci. Technol.* **62**, 172–179.
<https://doi.org/10.2166/wst.2010.276>

Yang, W., Zhou, H., Cicek, N., 2012. Removal mechanisms of 17 β -estradiol and 17 α -ethinylestradiol in membrane bioreactors. *Water Sci. Technol.* **66**, 1263–1269. <https://doi.org/10.2166/wst.2012.309>

Yu, J., He, C., Liu, X., Wu, J., Hu, Y., Zhang, Y., 2014. Removal of perfluorinated compounds by membrane bioreactor with powdered activated carbon (PAC): Adsorption onto sludge and PAC. *Desalination* **334**, 23–28.
<https://doi.org/10.1016/j.desal.2013.08.007>

Zhang, Q., Singh, S., Stuckey, D.C., 2017. Fouling reduction using adsorbents/flocculants in a submerged anaerobic membrane bioreactor. *Bioresour. Technol.* **239**, 226–235. <https://doi.org/10.1016/j.biortech.2017.05.022>

Zhang, S., Xiong, J., Zuo, X., Liao, W., Ma, C., He, J., Chen, Z., 2019a. Characteristics of the sludge filterability and microbial composition in PAC hybrid MBR: Effect of PAC replenishment ratio. *Biochem. Eng. J.* **145**, 10–17.
<https://doi.org/10.1016/j.bej.2019.02.001>

Zhang, S., Zuo, X., Xiong, J., Ma, C., Hu, B., 2019b. Effect of powdered activated carbon dosage on sludge properties and membrane bioreactor performance in a hybrid MBR-PAC system. *Environ. Technol. (United Kingdom)* **40**, 1156–1165. <https://doi.org/10.1080/09593330.2017.1417493>

Zhang, Y., Zhao, X., 2014. The effects of powdered activated carbon or ferric chloride on sludge characteristics and microorganisms in a membrane bioreactor. *Desalin. Water Treat.* **52**, 6868–6877.
<https://doi.org/10.1080/19443994.2013.822331>

Ziemba, C., Larivé, O., Reynaert, E., Huisman, T., Morgenroth, E., 2020. Linking transformations of organic carbon to

post-treatment performance in a biological water recycling system. *Sci. Total Environ.* 721.
<https://doi.org/10.1016/j.scitotenv.2020.137489>

Zouboulis, A.I., Gkotsis, P.K., Zamboulis, D.X., Mitrakas, M.G., 2017. Application of powdered activated carbon (PAC) for membrane fouling control in a pilot-scale MBR system. *Water Sci. Technol.* 75, 2350–2357.
<https://doi.org/10.2166/wst.2017.108>